Lorlatinib, an ALK inhibitor, can decrease CLIP1-LTK kinase activity since the kinase domains of LTK and ALK are highly similar, showing therapeutic effects on NSCLC patients with CLIP1-LTK fusion gene. Here, ALK is linked to non-small cell lung carcinoma.